Medpace Holdings, Inc. Announces Secondary Offering of Common Stock by Selling Shareholder

August 22, 2018 8:44 PM EDT

CINCINNATI--(BUSINESS WIRE)--Aug. 22, 2018-- Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced a secondary offering of 5,224,997 shares of its common stock by investment funds affiliated with Cinven Capital Management (V) General Partner Limited (the “Selling Shareholder”). The offering consists entirely of secondary shares of common stock to be sold by the Selling Shareholder. Medpace will not receive any proceeds from the sale of the shares of common stock by the Selling Shareholder.

Morgan Stanley is acting as the sole bookrunner for the offering. Morgan Stanley proposes to offer the shares of our common stock from time to time for sale in one or more transactions on the NASDAQ Global Select Market, in the over-the-counter market, through negotiated transactions or otherwise at market prices prevailing at the time of sale, at prices related to such prevailing market prices or negotiated prices, subject to their right to reject any order in whole or in part.

The offering will be made only by means of a prospectus supplement and an accompanying prospectus. Copies of the prospectus supplement, when available, and the accompanying prospectus relating to this offering may be obtained by contacting Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014.

A registration statement on Form S-3 (including a prospectus) relating to the securities being sold in the offering has been declared effective by the Securities and Exchange Commission. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.

About Medpace

Medpace is a scientifically-driven, global, full-service clinical contract research organization (CRO) providing Phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. Medpace’s mission is to accelerate the global development of safe and effective medical therapeutics through its high-science and disciplined operating approach that leverages local regulatory and deep therapeutic expertise across all major areas including oncology, cardiology, metabolic disease, endocrinology, central nervous system and anti-viral and anti-infective. Headquartered in Cincinnati, Ohio, Medpace employs approximately 2,700 people across 36 countries.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180822005666/en/

Source: Medpace Holdings, Inc.

Medpace Holdings, Inc.
Julie Hopkins, 513-579-9911 x12627
j.hopkins@medpace.com
or
Investor Contact:
investor@medpace.com